Key result
This review summarizes known RNA-targeting splicing modifiers, screening methods for novel modifiers, and the chemical space occupied by small-molecule splicing modifiers.
Why the study?
RNA splicing modifiers represent a promising pharmacological modality to expand the scope of drug targets and enrich the biomedical research toolbox.
RNA-targeting splicing modifiers represent a promising pharmacological modality to target previously 'undruggable' genes for various diseases.
No takes yet. Share an insight, caveat, or question.
May broaden options for undruggable cardiovascular targets; leaves open clinical translation pending prospective trials.
Tang et al. (2021) conducted a review in Diseases caused by aberrant splicing. RNA-targeting splicing modifiers was evaluated. This review summarizes known RNA-targeting splicing modifiers, screening methods for novel modifiers, and the chemical space occupied by small-molecule splicing modifiers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: